Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives

SIMPLE SUMMARY: Gene expression signatures were initially developed to take into account tumor biology for adjuvant chemotherapy decision and have become a standard option in hormone receptors-positive/HER2-negative early breast cancer. While recent randomized phase III studies have provided high le...

Descripción completa

Detalles Bibliográficos
Autores principales: Varnier, Romain, Sajous, Christophe, de Talhouet, Solène, Smentek, Colette, Péron, Julien, You, Benoît, Reverdy, Thibaut, Freyer, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508256/
https://www.ncbi.nlm.nih.gov/pubmed/34638325
http://dx.doi.org/10.3390/cancers13194840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508256/
https://www.ncbi.nlm.nih.gov/pubmed/34638325
http://dx.doi.org/10.3390/cancers13194840

Ejemplares similares